CO2017012947A2 - Inhibidores de tirosina-cinasas - Google Patents
Inhibidores de tirosina-cinasasInfo
- Publication number
- CO2017012947A2 CO2017012947A2 CONC2017/0012947A CO2017012947A CO2017012947A2 CO 2017012947 A2 CO2017012947 A2 CO 2017012947A2 CO 2017012947 A CO2017012947 A CO 2017012947A CO 2017012947 A2 CO2017012947 A2 CO 2017012947A2
- Authority
- CO
- Colombia
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- compounds
- btk
- diseases
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Diabetes (AREA)
Abstract
La presente divulgación proporciona compuestos que son inhibidores de tirosina-cinasas, en particular inhibidores de la tirosina-cinasa de Bruton (BTK), y, por lo tanto, son útiles para el tratamiento de enfermedades que se pueden tratar mediante la inhibición de BTK tales como el cáncer, enfermedades autoinmunitarias, inflamatorias y tromboembólicas. También se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170547P | 2015-06-03 | 2015-06-03 | |
| US201562271689P | 2015-12-28 | 2015-12-28 | |
| PCT/US2016/035588 WO2016196840A1 (en) | 2015-06-03 | 2016-06-02 | Tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017012947A2 true CO2017012947A2 (es) | 2018-03-28 |
Family
ID=56118090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0012947A CO2017012947A2 (es) | 2015-06-03 | 2017-12-15 | Inhibidores de tirosina-cinasas |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20180162861A1 (es) |
| EP (3) | EP3912979A1 (es) |
| JP (2) | JP6646072B2 (es) |
| KR (3) | KR102552653B1 (es) |
| CN (2) | CN106459049B (es) |
| AU (2) | AU2016270973B2 (es) |
| CA (1) | CA2987335A1 (es) |
| CL (2) | CL2017003073A1 (es) |
| CO (1) | CO2017012947A2 (es) |
| CR (1) | CR20170593A (es) |
| DK (1) | DK3303334T3 (es) |
| DO (1) | DOP2017000279A (es) |
| EA (1) | EA039006B1 (es) |
| ES (1) | ES2878030T3 (es) |
| HK (1) | HK1252378A1 (es) |
| HR (1) | HRP20211249T1 (es) |
| HU (1) | HUE055419T2 (es) |
| IL (2) | IL255946A (es) |
| LT (1) | LT3303334T (es) |
| MX (2) | MX395007B (es) |
| MY (1) | MY190548A (es) |
| PE (1) | PE20180521A1 (es) |
| PH (2) | PH12021551681A1 (es) |
| PL (1) | PL3303334T3 (es) |
| PT (1) | PT3303334T (es) |
| RS (1) | RS62290B1 (es) |
| SG (1) | SG10201912443XA (es) |
| SI (1) | SI3303334T1 (es) |
| TN (1) | TN2017000501A1 (es) |
| TW (2) | TWI810582B (es) |
| UA (1) | UA124090C2 (es) |
| WO (1) | WO2016196840A1 (es) |
| ZA (2) | ZA201708667B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013130619A1 (en) | 2012-02-27 | 2013-09-06 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
| PL2892900T3 (pl) | 2012-09-10 | 2018-02-28 | Principia Biopharma Inc. | Związki pyrazolopirymidonowe jako inhibitory kinazy |
| US10226782B2 (en) | 2013-11-29 | 2019-03-12 | Daizo Corporation | Content-accommodating container, content-accommodating product using same, discharge product, and discharge device |
| CA2939186C (en) | 2014-02-21 | 2023-03-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| SI3303334T1 (sl) * | 2015-06-03 | 2021-09-30 | Principia Biopharma Inc. | Zaviralci tirozin kinaz |
| MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| US10358446B2 (en) * | 2015-10-14 | 2019-07-23 | Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. | Bruton's tyrosine kinase inhibitors |
| MX390619B (es) | 2016-06-29 | 2025-03-21 | Principia Biopharma Inc | Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo |
| EP3487857B1 (en) * | 2016-07-25 | 2021-09-01 | Nerviano Medical Sciences S.r.l. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| EP3585789A1 (en) * | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| CN112424207B (zh) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | Nlrp3炎性小体抑制剂 |
| KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| DK3808747T3 (da) * | 2018-09-13 | 2025-02-03 | Kissei Pharmaceutical | Imidazopyridinon-forbindelse |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| MX2022004427A (es) | 2019-10-14 | 2022-07-12 | Principia Biopharma Inc | Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN113045484B (zh) * | 2019-12-27 | 2024-01-26 | 南京药石科技股份有限公司 | 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法 |
| CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法 |
| MX2022008875A (es) | 2020-01-20 | 2022-08-11 | Genzyme Corp | Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). |
| KR20220130184A (ko) | 2020-01-22 | 2022-09-26 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4125913A4 (en) * | 2020-03-30 | 2023-08-23 | IGIA Pharmaceuticals, Inc. | PEDIATRIC TYROSINE KINASE INHIBITOR FORMULATION |
| US20230270743A1 (en) * | 2020-08-10 | 2023-08-31 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Use of btk inhibitors in the treatment of diseases |
| KR20230051227A (ko) | 2020-08-14 | 2023-04-17 | 노파르티스 아게 | 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도 |
| WO2022090481A1 (en) | 2020-11-02 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| CA3201936A1 (en) * | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| CN116710452A (zh) * | 2020-12-23 | 2023-09-05 | 建新公司 | 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类 |
| US20240051955A1 (en) * | 2020-12-23 | 2024-02-15 | Genzyme Corporation | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| US20240217973A1 (en) * | 2021-04-16 | 2024-07-04 | Medshine Discovery Inc. | Imidazopyridine compounds and use thereof |
| WO2022223027A1 (zh) | 2021-04-23 | 2022-10-27 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| EP4342468A4 (en) * | 2021-05-21 | 2025-06-04 | Hangzhou Solipharma Co., Ltd. | Tolbrutinib salt and crystal form thereof, manufacturing process therefor, pharmaceutical composition therefrom and use thereof |
| CA3221129A1 (en) | 2021-06-11 | 2022-12-15 | Minhua Chen | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| JP2024533724A (ja) * | 2021-09-24 | 2024-09-12 | ドナルドソン，チャドウィック | 粘膜を通して薬剤を送達するための乾燥粉末発泡性製剤 |
| AU2022421837A1 (en) | 2021-12-21 | 2024-08-01 | Principia Biopharma Inc. | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| EP4490156A1 (en) * | 2022-03-09 | 2025-01-15 | Teva Pharmaceuticals International GmbH | Solid state forms of tolebrutinib and of tolebrutinib salts |
| US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
| JP2025520382A (ja) * | 2022-06-14 | 2025-07-03 | プリンシピア バイオファーマ インコーポレイテッド | トレブルチニブの製造方法 |
| JP2025521510A (ja) * | 2022-06-22 | 2025-07-10 | プリンシピア バイオファーマ インコーポレイテッド | 改変されたｂｔｋ阻害剤の作製方法 |
| IL318093A (en) | 2022-06-30 | 2025-02-01 | Principia Biopharma Inc | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| IL320166A (en) | 2022-10-11 | 2025-06-01 | Principia Biopharma Inc | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| CN118891260B (zh) * | 2022-11-07 | 2025-07-25 | 天津瑞程健达医药科技有限公司 | 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物 |
| EP4637726A1 (en) | 2022-12-20 | 2025-10-29 | Principia Biopharma Inc. | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| AU2024214470A1 (en) | 2023-02-01 | 2025-09-11 | Principia Biopharma Inc. | Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid |
| WO2025188862A1 (en) | 2024-03-06 | 2025-09-12 | Principia Biopharma Inc. | Methods of making tolebrutinib |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US7244744B2 (en) | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| BRPI0515316A (pt) * | 2004-09-14 | 2008-07-15 | Chiron Corp | compostos de imidazoquinolina |
| WO2006086634A2 (en) * | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| AU2011260961B9 (en) * | 2010-05-31 | 2015-02-26 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| EP2710006A1 (en) * | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| SI2710005T1 (sl) * | 2011-05-17 | 2017-03-31 | Principia Biopharma Inc. | Zaviralci tirozinske kinaze |
| DK2710007T3 (da) * | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
| BR122022001235B1 (pt) * | 2011-11-29 | 2023-04-11 | Ono Pharmaceutical Co., Ltd | Cristal de cloridrato derivado de purinona |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| US20160045503A1 (en) | 2012-06-18 | 2016-02-18 | Principia Biopharma Inc. | Formulations containing reversible covalent compounds |
| US8802697B2 (en) | 2012-07-11 | 2014-08-12 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| PL2892900T3 (pl) * | 2012-09-10 | 2018-02-28 | Principia Biopharma Inc. | Związki pyrazolopirymidonowe jako inhibitory kinazy |
| US20140142099A1 (en) * | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| SI3303334T1 (sl) * | 2015-06-03 | 2021-09-30 | Principia Biopharma Inc. | Zaviralci tirozin kinaz |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| US10358446B2 (en) | 2015-10-14 | 2019-07-23 | Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. | Bruton's tyrosine kinase inhibitors |
-
2016
- 2016-06-02 SI SI201631244T patent/SI3303334T1/sl unknown
- 2016-06-02 PH PH1/2021/551681A patent/PH12021551681A1/en unknown
- 2016-06-02 DK DK16728566.7T patent/DK3303334T3/da active
- 2016-06-02 HU HUE16728566A patent/HUE055419T2/hu unknown
- 2016-06-02 AU AU2016270973A patent/AU2016270973B2/en active Active
- 2016-06-02 PL PL16728566T patent/PL3303334T3/pl unknown
- 2016-06-02 MY MYPI2017704576A patent/MY190548A/en unknown
- 2016-06-02 EP EP21169631.5A patent/EP3912979A1/en active Pending
- 2016-06-02 TW TW110121130A patent/TWI810582B/zh active
- 2016-06-02 KR KR1020177037609A patent/KR102552653B1/ko active Active
- 2016-06-02 LT LTEPPCT/US2016/035588T patent/LT3303334T/lt unknown
- 2016-06-02 CN CN201680000891.8A patent/CN106459049B/zh active Active
- 2016-06-02 CR CR20170593A patent/CR20170593A/es unknown
- 2016-06-02 JP JP2017562758A patent/JP6646072B2/ja active Active
- 2016-06-02 TN TNP/2017/000501A patent/TN2017000501A1/en unknown
- 2016-06-02 EP EP22188609.6A patent/EP4112618A1/en active Pending
- 2016-06-02 KR KR1020227035399A patent/KR102666352B1/ko active Active
- 2016-06-02 SG SG10201912443XA patent/SG10201912443XA/en unknown
- 2016-06-02 RS RS20211083A patent/RS62290B1/sr unknown
- 2016-06-02 HK HK18111674.0A patent/HK1252378A1/zh unknown
- 2016-06-02 EP EP16728566.7A patent/EP3303334B1/en active Active
- 2016-06-02 PE PE2017002512A patent/PE20180521A1/es unknown
- 2016-06-02 EA EA201792529A patent/EA039006B1/ru unknown
- 2016-06-02 CA CA2987335A patent/CA2987335A1/en active Pending
- 2016-06-02 UA UAA201712794A patent/UA124090C2/uk unknown
- 2016-06-02 CN CN202011284728.3A patent/CN113149983B/zh active Active
- 2016-06-02 TW TW105117466A patent/TWI732765B/zh active
- 2016-06-02 KR KR1020247015612A patent/KR20240070721A/ko active Pending
- 2016-06-02 MX MX2021006571A patent/MX395007B/es unknown
- 2016-06-02 PH PH1/2017/502203A patent/PH12017502203B1/en unknown
- 2016-06-02 MX MX2017015470A patent/MX383213B/es unknown
- 2016-06-02 PT PT167285667T patent/PT3303334T/pt unknown
- 2016-06-02 ES ES16728566T patent/ES2878030T3/es active Active
- 2016-06-02 US US15/578,623 patent/US20180162861A1/en not_active Abandoned
- 2016-06-02 HR HRP20211249TT patent/HRP20211249T1/hr unknown
- 2016-06-02 WO PCT/US2016/035588 patent/WO2016196840A1/en not_active Ceased
-
2017
- 2017-01-19 US US15/410,716 patent/US9688676B2/en active Active
- 2017-11-27 IL IL255946A patent/IL255946A/en active IP Right Grant
- 2017-12-01 DO DO2017000279A patent/DOP2017000279A/es unknown
- 2017-12-01 CL CL2017003073A patent/CL2017003073A1/es unknown
- 2017-12-15 CO CONC2017/0012947A patent/CO2017012947A2/es unknown
- 2017-12-19 ZA ZA2017/08667A patent/ZA201708667B/en unknown
-
2019
- 2019-07-31 CL CL2019002150A patent/CL2019002150A1/es unknown
-
2020
- 2020-01-08 JP JP2020001139A patent/JP6985433B2/ja active Active
- 2020-05-26 AU AU2020203447A patent/AU2020203447B2/en active Active
- 2020-09-23 US US17/029,184 patent/US20210171526A1/en not_active Abandoned
- 2020-12-07 IL IL279258A patent/IL279258B/en unknown
-
2022
- 2022-10-27 US US17/974,613 patent/US20230151012A1/en not_active Abandoned
-
2024
- 2024-02-13 ZA ZA2024/01324A patent/ZA202401324B/en unknown
- 2024-11-26 US US18/960,997 patent/US20250197402A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012947A2 (es) | Inhibidores de tirosina-cinasas | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
| MX361815B (es) | Compuestos pirazolopirimidinicos como inhibidores de cinasas. | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| NZ729603A (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| MX382607B (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| UY36419A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
| MX2018001315A (es) | Inhibidores de fucosidasa. | |
| MX384259B (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
| AR131653A2 (es) | Inhibidores de tirosina quinasa | |
| ECSP18000097A (es) | Inhibidores de tirosina-cinasas | |
| HK1230963A1 (en) | Novel methods for treating cancer |